US sickle cell gene-therapy pricing is decided by Medicaid concentration and CMS's outcomes-based access model, not by the $2.2-3.1M sticker price alone.
The US sickle cell payer question stopped being whether Casgevy and Lyfgenia are covered and became what net price CMS's Cell and Gene Therapy Access Model actually produces once the roughly $2.2 million and $3.1 million list prices pass through a Medicaid-dominant population. Sixty to seventy percent of US SCD patients are Medicaid-insured, concentrated in Southern states, so the statutory 23.1 percent rebate plus negotiated supplemental rebates does most of the gross-to-net work before any state ever signs an outcomes contract. CGTA lets participating state Medicaid programs tie manufacturer payment to durable vaso-occlusive-crisis freedom, and a best-price rebate waiver exists specifically so that outcomes-linked payment does not trigger a punitive best-price recalculation across a manufacturer's entire book of business.
ICER has already put a number on what it considers fair, without waiting for a manufacturer to defend one: a $1.5 to $1.9 million fair-value ceiling for Casgevy, public and citable in any payer negotiation. Below that ceiling sits a far cheaper, mandatory checkpoint. Every payer requires a documented hydroxyurea trial at maximum tolerated dose for at least six months, a roughly $600-a-year prerequisite, before authorizing either gene therapy. Because only 25 to 30 percent of eligible patients are even on hydroxyurea today, that step-edit adds real months to an access pathway that already runs through qualified-center referral, apheresis, and myeloablative conditioning. Lyfgenia's boxed warning for hematologic malignancy compounds the friction, since most commercial plans now position Casgevy as preferred within the gene-therapy class.
US sickle cell gene-therapy pricing — list price versus the CGTA-adjusted net
| Agent | Access Route | List Price | Net-Price Mechanism | Key Payer Constraint |
|---|---|---|---|---|
| Casgevy (exagamglogene autotemcel) | One-time; qualified center; CGTA-eligible | ~$2.2M | Medicaid outcomes contract (CGTA) plus statutory/supplemental rebate; ICER ceiling $1.5–1.9M | Preferred within gene-therapy class; requires documented hydroxyurea MTD trial ≥6 months |
| Lyfgenia (lovotibeglogene autotemcel) | One-time; qualified center; CGTA-eligible | ~$3.1M | Same CGTA mechanism; boxed warning drives formulary hesitancy | Often non-preferred vs Casgevy; same hydroxyurea step-edit |
| Hydroxyurea (generic) | Part D / pharmacy; no PA | ~$600–1,200/yr | Universal step-edit prerequisite before gene-therapy authorization | Only 25–30% of eligible patients currently on it |
Sources: CMS Cell and Gene Therapy Access Model documentation 2024; ICER 2024 sickle cell disease gene therapy assessment; FDA product labeling (Casgevy, Lyfgenia); manufacturer list-price announcements; ASH 2020 SCD guidelines.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- CGTA outcomes-based contract mechanics
- the statutory 23.1% rebate plus supplemental layer
- why the best-price waiver is the enabling condition for outcomes-linked payment
Delivers
- ICER's $1.5-1.9M fair-value ceiling and its methodology
- the gap between list price and ICER's ceiling
- positioning implications for a manufacturer's value story
Delivers
- The six-month hydroxyurea MTD prerequisite and its effect on time-to-authorization
- the Casgevy-preferred formulary split
- GTN waterfall decomposition by payer channel
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why Medicaid concentration and CMS's outcomes-based model, not list price, decide the realized net
- Pressure-tested against ICER's published fair-value ceiling before the rest of the model is built out
- Casgevy and Lyfgenia list price decomposed against the CGTA-adjusted net
- Where the $1.5-1.9M ICER ceiling sits against each
- The 23.1% statutory rebate plus supplemental layer
- Why the best-price waiver is the enabling condition for CGTA's outcomes contracts
- Casgevy-preferred vs Lyfgenia non-preferred positioning across commercial plans
- What the analogue split implies for a third entrant's own formulary strategy
- ICER's $1.5-1.9M fair-value ceiling methodology
- The ~$600/year hydroxyurea backbone as the comparator ICER anchors against
- The gross-to-net waterfall decomposed by payer channel
- How the six-month step-edit prerequisite adds time, not just cost, to the waterfall
- Priority Medicaid MCO states: Georgia, Texas, New York, Maryland
- Conservative, base, and aggressive revenue scenarios tied to CGTA state adoption pace
- The open pricing questions your team must close before the US launch price is locked
- Structured for an internal pricing committee session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx pricing model is built from primary regulatory sources (CMS, FDA, ICER) and live payer-policy documentation, not secondary summaries. Findings are independently verified before inclusion.
Sickle cell disease US pricing sources: CMS Cell and Gene Therapy Access Model documentation 2024, ICER's 2024 sickle cell disease gene therapy assessment, FDA product labeling, manufacturer list-price announcements, and ASH 2020 SCD guidelines.
- CGTA outcomes-based contract structure and the best-price rebate waiver verified against CMS Cell and Gene Therapy Access Model documentation 2024
- ICER's $1.5-1.9M fair-value ceiling verified against the ICER 2024 sickle cell disease gene therapy assessment
- Hydroxyurea step-edit prerequisite and utilisation gap cross-checked against ASH 2020 SCD guidelines and FDA product labeling
Frequently asked questions
Commission this model
AXLRx delivers sickle cell disease pricing strategy models built for market access and pricing teams navigating CMS's CGTA mechanism and Medicaid concentration. Custom model in 72 hours.
Specify your indication, payer channel, and comparator scope.
AXLRx analyst confirms pricing mechanism assumptions and WTP threshold before building.
Research-verified pricing model in 72 hours with optional analyst readout.